- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
The company has spent $600 million weighing a potential breakup.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
So says a proxy filing made after trading on Tuesday, as a couple of suitors included contingent value rights in their bids for the marketer of prostate cancer drug, Xtandi.